These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37768671)

  • 21. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
    Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
    [No Abstract]   [Full Text] [Related]  

  • 22. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
    Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy.
    Yarlas A; Lovley A; Brown D; Vera-Llonch M; Khella S; Karam C
    BMC Neurol; 2023 Mar; 23(1):108. PubMed ID: 36932361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
    [No Abstract]   [Full Text] [Related]  

  • 25. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
    Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S; Aldinc E; Polydefkis M; Adams D; Coelho T; Ueda M; Hale C; Vest J; Nioi P;
    Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
    Luigetti M; Antonini G; Di Paolantonio A; Gentile L; Grandis M; Leonardi L; Lozza A; Manganelli F; Mazzeo A; Mussinelli R; My F; Obici L; Maria Pennisi E; Romozzi M; Russo M; Sabatelli M; Salvalaggio A; Tagliapietra M; Tozza S
    Eur J Neurol; 2022 Jul; 29(7):2148-2155. PubMed ID: 35289020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis.
    Diep JK; Yu RZ; Viney NJ; Schneider E; Guo S; Henry S; Monia B; Geary R; Wang Y
    Br J Clin Pharmacol; 2022 Dec; 88(12):5389-5398. PubMed ID: 35869634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
    Quan D; Obici L; Berk JL; Ando Y; Aldinc E; White MT; Adams D
    Amyloid; 2023 Mar; 30(1):49-58. PubMed ID: 36120830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.
    Dyck PJB; Kincaid JC; Wiesman JF; Polydefkis M; Litchy WJ; Mauermann ML; Ackermann EJ; Guthrie S; Pollock M; Jung SW; Baker BF; Dyck PJ
    Muscle Nerve; 2020 Oct; 62(4):502-508. PubMed ID: 32654212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.
    Narayanan P; Curtis BR; Shen L; Schneider E; Tami JA; Paz S; Burel SA; Tai LJ; Machemer T; Kwoh TJ; Xia S; Shattil SJ; Witztum JL; Engelhardt JA; Henry SP; Monia BP; Hughes SG
    Nucleic Acid Ther; 2020 Apr; 30(2):94-103. PubMed ID: 32043907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
    Schmidt HH; Wixner J; Planté-Bordeneuve V; Muñoz-Beamud F; Lladó L; Gillmore JD; Mazzeo A; Li X; Arum S; Jay PY; Adams D;
    Am J Transplant; 2022 Jun; 22(6):1646-1657. PubMed ID: 35213769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
    Dyck PJB; Coelho T; Waddington Cruz M; Brannagan TH; Khella S; Karam C; Berk JL; Polydefkis MJ; Kincaid JC; Wiesman JF; Litchy WJ; Mauermann ML; Ackermann EJ; Baker BF; Jung SW; Guthrie S; Pollock M; Dyck PJ
    Muscle Nerve; 2020 Oct; 62(4):509-515. PubMed ID: 32654156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
    Benson MD; Dasgupta NR; Monia BP
    Neurodegener Dis Manag; 2019 Feb; 9(1):25-30. PubMed ID: 30561247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
    J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
    Nie T; Heo YA; Shirley M
    Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
    Obici L; Ajroud-Driss S; Lin KP; Berk JL; Gillmore JD; Kale P; Koike H; Danese D; Aldinc E; Chen C; Vest J; Adams D;
    Neurol Ther; 2023 Oct; 12(5):1759-1775. PubMed ID: 37523143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gene therapy options for hereditary transthyretin-related amyloidosis].
    Schilling M
    Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
    Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
    J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.